NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Arlo Technologies, Inc. (NYSE: ARLO)
Class Period: Investors who purchased shares pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the August 3, 2018 Initial Public Offering
Lead Plaintiff Deadline: March 25, 2019
Join the action: https://www.zlk.com/pslra-1/arlo-technologies-inc-loss-form?wire=3
The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v) Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and (vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.
To learn more about the Arlo Technologies, Inc. class action contact jlevi@levikorsinsky.com.
Markel Corporation (NYSE: MKL)
Class Period: July 26, 2017 - December 6, 2018
Lead Plaintiff Deadline: March 12, 2019
Join the action: https://www.zlk.com/pslra-1/markel-corporation-loss-form?wire=3
About the lawsuit: During the class period, Markel Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s subsidiaries did not appropriately record loss reserves; (2) as a result, the loss reserves would need to be adjusted and/or restated; (3) these misleading accounting practices would lead to regulatory scrutiny and financial loss to investors; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the Markel Corporation class action contact jlevi@levikorsinsky.com.
Activision Blizzard, Inc. (NASDAQ: ATVI)
Class Period: August 2, 2018 - January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
Join the action: https://www.zlk.com/pslra-1/activision-blizzard-inc-loss-form?wire=3
About the lawsuit: Activision Blizzard, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie's partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies' relationship would foreseeably have a significant negative impact on Activision Blizzard's revenues; and (iii) as a result, Activision Blizzard's public statements were materially false and misleading at all relevant times.
To learn more about the Activision Blizzard, Inc. class action contact jlevi@levikorsinsky.com.
Amarin Corporation (NASDAQGM: AMRN)
Class Period: September 24, 2018 - November 9, 2018
Lead Plaintiff Deadline: April 23, 2019
Join the action: https://www.zlk.com/pslra-1/amarin-corporation-loss-form?wire=3
About the lawsuit: Throughout the class period, Amarin Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all relevant times.
To learn more about the Amarin Corporation class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com